Slide 1: IKS Health Q4 FY25 Investor Presentation
IKS Health Q4 FY 25 Investor Presentation 1
Slide 2: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 3: IKS Health - a comprehensive healthcare enablement platform empowering provider organizations
IKS Health - a comprehensive healthcare enablement platform empowering provider organizations US$222bn / US$34bn US$5tn TAM / Outsourced Market 8% / 12% Total TAM / Outsourced Market US Healthcare (CY2023) Addressable Expenditure (CY2024) CAGR (2023-2028E) Market1,2 (Now expanded TAM by another $50B
Slide 4: IKS Health enables care transformation across the patient journey
IKS Health enables care transformation across the patient journey Automation Level Automation Level Automation Level Automation Level Optimized Patient Patient Prospective Pre-Visit Scheduling Financial Engagement Clinical Chart Clearance Hub Reviews Automation Level Automation Level Automation Leve
Slide 5: $45B+ Equity Investment in HCIT 2021-2024 focused largely on Point Solutions
$45B+* Equity Investment in HCIT 2021-2024 focused largely on Point Solutions General catalyst owned Commure acquired Scribing player Augmedix in July 2024 for R1 RCM was acquired by TowerBrook Capital Partners $139 mn. Its last reported net loss was $(19) and Clayton, Dubilier & Rice at a valuation
Slide 6: Q4 - Strong growth while delivering continuous margin expansion
Q4 - Strong growth while delivering continuous margin expansion Deep Client Globally Diversified Growth At Scale Strong Margin Profile Relationships Workforce INR 7240 mn 450+ 31% 12,661 Revenue from Enterprise level EBITDA Total Employees Operations customers 17% INR 2,842 mn / 39% 20% 2,294 / 473 Yo
Slide 7: Key Client Wins including 3 large platform deals
Key Client Wins including 3 large platform deals Implementation of the IKS Health care enablement platform at Sky Lakes to deliver outstanding care and Community owned health ensure financial sustainability across hospital and clinical settings system in Oregon Expanded partnership with Western Washi
Slide 8: Awards and Recognition
Awards and Recognition IKS Health Received 2 New Recognitions in Black Book Research 2025 Rankings IKS Health has been ranked #1 in Clinical Documentation for the 12th consecutive year and #1 in Medical Coding for the 3rd year in a row. These accolades follow our recent achievement of #1 Ranking in
Slide 9: Q4 FY25: Growing faster than market with improving margins
Q4 FY25: Growing faster than market with improving margins Revenue EBITDA INR Mn INR Mn 2,262 7,240 16.8% YoY 2,006 68.2% YoY 6,572 6,200 1,344 31.2% 10.2% QoQ 30.5% 12.7% QoQ 21.7% Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 PAT Adjusted PAT* INR Mn INR Mn 1,478 1,646 1,297 132.5% YoY 1,455 108
Slide 10: Q4 FY25 - Improving EPS and maintaining high ROE
Q4 FY25 - Improving EPS and maintaining high ROE EPS ₹ ROE % 131.5% YoY 13.9% QoQ EPS is calculated as profit for the period divided by weighted average Return on Equity is calculated as profit for the period divided by total number of equity shares as defined in IND AS 33. equity at the end of the per
Slide 11: FY25 - Strong growth while delivering continuous margin expansion
FY25 - Strong growth while delivering continuous margin expansion Deep Client Globally Diversified Growth At Scale Strong Margin Profile Relationships Workforce INR 26,640 mn 450+ 30% 12,661 Revenue from Enterprise level EBITDA Total Employees Operations customers 47% INR 9,230 mn / 35% 18% 2,294 / 47
Slide 12: FY25: Strong EBITDA and PAT growth
FY25: Strong EBITDA and PAT growth Revenue EBITDA INR Mn INR Mn 26,640 7,911 18,179 5,287 46.5% YoY 49.6% YoY 28.5% 29.5% 29.1% 29.7% FY 24 FY 25 FY 24 FY 25 PAT Adjusted PAT* INR Mn INR Mn 4,861 5,504 3,705 3,961 31.2% YoY 38.9% YoY 20.4% 18.2% 21.8% 20.7% FY 24 FY 25 FY 24 FY 25 *Adjusted PAT is a
Slide 13: FY 25 - Improving EPS and maintaining high ROE
FY 25 - Improving EPS and maintaining high ROE EPS ₹ ROE % 29 22 30.6% YoY FY 24 FY 25 EPS is calculated as profit for the period divided by weighted average Return on Equity is calculated as profit for the period divided by total number of equity shares as defined in IND AS 33. equity at the end of th
Slide 14: FY 25 - Strong cash generation supporting growth aspirations
FY 25 - Strong cash generation supporting growth aspirations OCF & FCF Net Debt INR Mn INR Mn 43.2% OCF 55.6% FCF Reported OCF and FCF are impacted by upfront guarantee payment of economic value add made to a new customer, Palomar for Rs 1,390 mn in FY 25 and acquisition related payments in FY 24 14
Slide 15: Financials - Summary INR millions
Financials - Summary INR millions INR Mn Particulars Q4 FY 25 Q3 FY 25 QoQ% Q4 FY 24 YoY% FY 25 FY 24 YoY% Revenue 7,240 6,572 10.2% 6,200 16.8% 26,640 18,179 46.5% Other Income - Operating* - 134 -100.0% 73 -100.0% 176 73 141.2% Forex Gain/ (Loss) (24) 58 -141.2% 24 -199.6% 38 (22) -270.1% Employee
Slide 16: Other KPI Metrics - Yearly
Other KPI Metrics - Yearly Particulars FY 25 FY 24** Adjusted EBITDA per employee* 0.63 0.54 Revenue from Top 10 customers INR mn 9,230 7,937 Contribution from Top 10 customers 34.6% 43.7% Revenue from Top 5 customers INR mn 5,828 5,016 Contribution from Top 5 customers 21.9% 27.6% Ageing of Top 10
Slide 17: Other KPI Metrics - Quarterly
Other KPI Metrics - Quarterly Particulars Q4 FY 25 Q3 FY 25 Q4 FY 24 Annualised Adjusted EBITDA per employee in INR mn 0.76 0.61 0.41 Revenue from Top 10 customers INR mn 2,842 2,724 2,185 Contribution from Top 10 customers 39.3% 41.5% 35.2% Revenue from Top 5 customers INR mn 1,944 1,806 1,370 Cont
Slide 18: Join the Movement
Join the Movement Grow, Scale, Thrive